Form 8-K - Current report:
SEC Accession No. 0001104659-26-040171
Filing Date
2026-04-07
Accepted
2026-04-07 08:35:16
Documents
15
Period of Report
2026-04-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2611272d1_8k.htm   iXBRL 8-K 55414
2 EXHIBIT 4.1 tm2611272d1_ex4-1.htm EX-4.1 134126
3 EXHIBIT 4.2 tm2611272d1_ex4-2.htm EX-4.2 91009
4 EXHIBIT 10.1 tm2611272d1_ex10-1.htm EX-10.1 299724
5 EXHIBIT 99.1 tm2611272d1_ex99-1.htm EX-99.1 9922
  Complete submission text file 0001104659-26-040171.txt   892868

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA rnaz-20260406.xsd EX-101.SCH 3053
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE rnaz-20260406_lab.xml EX-101.LAB 34239
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rnaz-20260406_pre.xml EX-101.PRE 22384
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2611272d1_8k_htm.xml XML 3326
Mailing Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109
Business Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109 857-301-6857
Transcode Therapeutics, Inc. (Filer) CIK: 0001829635 (see all company filings)

EIN.: 811065054 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40363 | Film No.: 26843042
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)